Tags

Type your tag names separated by a space and hit enter

Effect of Efavirenz on Endogenous Progesterone Concentrations and Contraceptive Outcomes among Ugandan HIV Infected Women Coadministering Ethinylestradiol/Levonorgestrel.
AIDS Res Treat. 2017; 2017:6531709.AR

Abstract

This study assessed the effect of efavirenz mid-dose plasma concentrations on mid-luteal endogenous progesterone concentrations and contraceptive outcomes among 49 HIV infected women coadministering ethinylestradiol/levonorgestrel, including 34 HIV positive women on Highly Active Antiretroviral Therapy (HAART) and 15 HAART naïve HIV infected women, purposively selected from Mulago Hospital, Uganda. A blood sample was collected once between days 20 and 22 of each woman's menstrual cycle for measuring endogenous progesterone and efavirenz concentrations by electrochemiluminescence technology and High Performance Liquid Chromatography (HPLC), respectively. Descriptive statistical analysis and correlation and logistic regression analysis were done using SPSS v.21 and R3.1. Efavirenz showed a weak positive linear relationship with endogenous progesterone at efavirenz concentrations below 12 μg/ml. Based on serum endogenous progesterone, the observed hormonal contraceptives failure rate (24.5%) was higher than expected (maximum 8%). A higher proportion of HIV positive women on efavirenz based HAART (26.5%) was at risk of contraceptive failure than their HIV infected HAART naïve counterparts (20%) though it was not statistically significant (p = 0.63). Efavirenz mid-dose plasma concentrations seem to have no significant effect on mid-luteal endogenous progesterone concentrations and contraceptive outcomes among HIV infected Ugandan women coadministering ethinylestradiol/levonorgestrel oral pills.

Authors+Show Affiliations

Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, P.O. Box 7062, Kampala, Uganda.Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, P.O. Box 7062, Kampala, Uganda.Department of Obstetrics and Gynaecology, College of Health Sciences, Makerere University, P.O. Box 7062, Kampala, Uganda.Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, P.O. Box 7062, Kampala, Uganda.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28831309

Citation

Munkwase, Grant, et al. "Effect of Efavirenz On Endogenous Progesterone Concentrations and Contraceptive Outcomes Among Ugandan HIV Infected Women Coadministering Ethinylestradiol/Levonorgestrel." AIDS Research and Treatment, vol. 2017, 2017, p. 6531709.
Munkwase G, Bisaso KR, Kakaire O, et al. Effect of Efavirenz on Endogenous Progesterone Concentrations and Contraceptive Outcomes among Ugandan HIV Infected Women Coadministering Ethinylestradiol/Levonorgestrel. AIDS Res Treat. 2017;2017:6531709.
Munkwase, G., Bisaso, K. R., Kakaire, O., & Nanzigu, S. (2017). Effect of Efavirenz on Endogenous Progesterone Concentrations and Contraceptive Outcomes among Ugandan HIV Infected Women Coadministering Ethinylestradiol/Levonorgestrel. AIDS Research and Treatment, 2017, 6531709. https://doi.org/10.1155/2017/6531709
Munkwase G, et al. Effect of Efavirenz On Endogenous Progesterone Concentrations and Contraceptive Outcomes Among Ugandan HIV Infected Women Coadministering Ethinylestradiol/Levonorgestrel. AIDS Res Treat. 2017;2017:6531709. PubMed PMID: 28831309.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of Efavirenz on Endogenous Progesterone Concentrations and Contraceptive Outcomes among Ugandan HIV Infected Women Coadministering Ethinylestradiol/Levonorgestrel. AU - Munkwase,Grant, AU - Bisaso,Kuteesa R, AU - Kakaire,Othman, AU - Nanzigu,Sarah, Y1 - 2017/07/31/ PY - 2017/03/21/received PY - 2017/06/12/revised PY - 2017/07/02/accepted PY - 2017/8/24/entrez PY - 2017/8/24/pubmed PY - 2017/8/24/medline SP - 6531709 EP - 6531709 JF - AIDS research and treatment JO - AIDS Res Treat VL - 2017 N2 - This study assessed the effect of efavirenz mid-dose plasma concentrations on mid-luteal endogenous progesterone concentrations and contraceptive outcomes among 49 HIV infected women coadministering ethinylestradiol/levonorgestrel, including 34 HIV positive women on Highly Active Antiretroviral Therapy (HAART) and 15 HAART naïve HIV infected women, purposively selected from Mulago Hospital, Uganda. A blood sample was collected once between days 20 and 22 of each woman's menstrual cycle for measuring endogenous progesterone and efavirenz concentrations by electrochemiluminescence technology and High Performance Liquid Chromatography (HPLC), respectively. Descriptive statistical analysis and correlation and logistic regression analysis were done using SPSS v.21 and R3.1. Efavirenz showed a weak positive linear relationship with endogenous progesterone at efavirenz concentrations below 12 μg/ml. Based on serum endogenous progesterone, the observed hormonal contraceptives failure rate (24.5%) was higher than expected (maximum 8%). A higher proportion of HIV positive women on efavirenz based HAART (26.5%) was at risk of contraceptive failure than their HIV infected HAART naïve counterparts (20%) though it was not statistically significant (p = 0.63). Efavirenz mid-dose plasma concentrations seem to have no significant effect on mid-luteal endogenous progesterone concentrations and contraceptive outcomes among HIV infected Ugandan women coadministering ethinylestradiol/levonorgestrel oral pills. SN - 2090-1240 UR - https://www.unboundmedicine.com/medline/citation/28831309/Effect_of_Efavirenz_on_Endogenous_Progesterone_Concentrations_and_Contraceptive_Outcomes_among_Ugandan_HIV_Infected_Women_Coadministering_Ethinylestradiol/Levonorgestrel_ L2 - https://doi.org/10.1155/2017/6531709 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.